4D pharma announces positive interim results from the Phase I/II study of the combination of MRx0518 and KEYTRUDA(R) (pembrolizumab) for the treatment of renal cell carcinoma Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of StudyCompany to Host Conference Call and Webcast Today Mar.
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® for the Treatment of Renal Cell Carcinoma . | March 23, 2022
4D pharma announces positive interim results from the Phase I/II study of the combination of MRx0518 and KEYTRUDA(R) (pembrolizumab) for the treatment of renal cell carcinoma Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of StudyCompany to Host Conference Call and Webcast Today Mar.